166 related articles for article (PubMed ID: 28576633)
1. Design, synthesis and biological evaluation of sulfonamide-substituted diphenylpyrimidine derivatives (Sul-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with antitumor activity.
Qu M; Liu Z; Zhao D; Wang C; Zhang J; Tang Z; Liu K; Shu X; Yuan H; Ma X
Bioorg Med Chem; 2017 Aug; 25(15):3989-3996. PubMed ID: 28576633
[TBL] [Abstract][Full Text] [Related]
2. Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with enhanced activity against pancreatic cancer cell lines.
Liu H; Wu B; Ge Y; Huang J; Song S; Wang C; Yao J; Liu K; Li Y; Li Y; Ma X
Bioorg Med Chem; 2017 Dec; 25(24):6313-6321. PubMed ID: 29102081
[TBL] [Abstract][Full Text] [Related]
3. Structure-based modification of carbonyl-diphenylpyrimidines (Car-DPPYs) as a novel focal adhesion kinase (FAK) inhibitor against various stubborn cancer cells.
Wang L; Ai M; Yu J; Jin L; Wang C; Liu Z; Shu X; Tang Z; Liu K; Luo H; Guan W; Sun X; Ma X
Eur J Med Chem; 2019 Jun; 172():154-162. PubMed ID: 30978560
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia.
Liu H; Qu M; Xu L; Han X; Wang C; Shu X; Yao J; Liu K; Peng J; Li Y; Ma X
Eur J Med Chem; 2017 Jul; 135():60-69. PubMed ID: 28432946
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines.
Ge Y; Yang H; Wang C; Meng Q; Li L; Sun H; Zhen Y; Liu K; Li Y; Ma X
Bioorg Med Chem; 2017 Jan; 25(2):765-772. PubMed ID: 27956037
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC).
Song Z; Huang S; Yu H; Jiang Y; Wang C; Meng Q; Shu X; Sun H; Liu K; Li Y; Ma X
Eur J Med Chem; 2017 Jun; 133():329-339. PubMed ID: 28395219
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors.
Wang R; Yu S; Zhao X; Chen Y; Yang B; Wu T; Hao C; Zhao D; Cheng M
Eur J Med Chem; 2020 Feb; 188():112024. PubMed ID: 31923858
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of 2,4-diamino pyrimidine derivatives as potent FAK inhibitors with anti-cancer and anti-angiogenesis activities.
Wang S; Zhang RH; Zhang H; Wang YC; Yang D; Zhao YL; Yan GY; Xu GB; Guan HY; Zhou YH; Cui DB; Liu T; Li YJ; Liao SG; Zhou M
Eur J Med Chem; 2021 Oct; 222():113573. PubMed ID: 34091209
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study.
Wang R; Zhao X; Yu S; Chen Y; Cui H; Wu T; Hao C; Zhao D; Cheng M
Bioorg Chem; 2020 Sep; 102():104092. PubMed ID: 32707280
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of ring-fused pyrazoloamino pyridine/pyrimidine derivatives as potential FAK inhibitors.
Xie H; Lin X; Zhang Y; Tan F; Chi B; Peng Z; Dong W; An D
Bioorg Med Chem Lett; 2020 Nov; 30(21):127459. PubMed ID: 32784087
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of diphenylpyrimidine derivatives (DPPYs) as potential dual EGFR T790M and FAK inhibitors against a diverse range of cancer cell lines.
Ai M; Wang C; Tang Z; Liu K; Sun X; Ma T; Li Y; Ma X; Li L; Chen L
Bioorg Chem; 2020 Jan; 94():103408. PubMed ID: 31706682
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents.
Wang R; Chen Y; Zhao X; Yu S; Yang B; Wu T; Guo J; Hao C; Zhao D; Cheng M
Eur J Med Chem; 2019 Dec; 183():111716. PubMed ID: 31550660
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.
Roberts WG; Ung E; Whalen P; Cooper B; Hulford C; Autry C; Richter D; Emerson E; Lin J; Kath J; Coleman K; Yao L; Martinez-Alsina L; Lorenzen M; Berliner M; Luzzio M; Patel N; Schmitt E; LaGreca S; Jani J; Wessel M; Marr E; Griffor M; Vajdos F
Cancer Res; 2008 Mar; 68(6):1935-44. PubMed ID: 18339875
[TBL] [Abstract][Full Text] [Related]
14. Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.
Zhao D; Huang S; Qu M; Wang C; Liu Z; Li Z; Peng J; Liu K; Li Y; Ma X; Shu X
Eur J Med Chem; 2017 Jan; 126():444-455. PubMed ID: 27912175
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells.
Shi X; Quan Y; Wang Y; Wang Y; Li Y
Bioorg Med Chem Lett; 2021 Feb; 33():127725. PubMed ID: 33316409
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities.
Su Y; Li R; Ning X; Lin Z; Zhao X; Zhou J; Liu J; Jin Y; Yin Y
Eur J Med Chem; 2019 Sep; 177():32-46. PubMed ID: 31129452
[TBL] [Abstract][Full Text] [Related]
17. C-2 (E)-4-(Styryl)aniline substituted diphenylpyrimidine derivatives (Sty-DPPYs) as specific kinase inhibitors targeting clinical resistance related EGFR
Song A; Zhang J; Ge Y; Wang C; Meng Q; Tang Z; Peng J; Liu K; Li Y; Ma X
Bioorg Med Chem; 2017 May; 25(10):2724-2729. PubMed ID: 28385595
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and evaluation of novel imidazo[1,2-a][1,3,5]triazines and their derivatives as focal adhesion kinase inhibitors with antitumor activity.
Dao P; Smith N; Tomkiewicz-Raulet C; Yen-Pon E; Camacho-Artacho M; Lietha D; Herbeuval JP; Coumoul X; Garbay C; Chen H
J Med Chem; 2015 Jan; 58(1):237-51. PubMed ID: 25180654
[TBL] [Abstract][Full Text] [Related]
19. Rational Design and Synthesis of Diverse Pyrimidine Molecules Bearing Sulfonamide Moiety as Novel ERK Inhibitors.
Halawa AH; Eskandrani AA; Elgammal WE; Hassan SM; Hassan AH; Ebrahim HY; Mehany ABM; El-Agrody AM; Okasha RM
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717402
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 2,4-diarylaminopyrimidine derivatives bearing sulfonamide moiety as novel FAK inhibitors.
Li R; Gong L; Sun J; Liang Z; He J; Huang J; Ning X; Song H; Li R; Zhang Q; Lin Z; Yin Y
Bioorg Chem; 2024 Mar; 144():107134. PubMed ID: 38237389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
